{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:59:52Z","timestamp":1789340392881,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.autrev.2023.103421","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T12:11:20Z","timestamp":1692879080000},"page":"103421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Should ACR\/EULAR criteria be revised changing the RF and ACPA scores?"],"prefix":"10.1016","volume":"23","author":[{"given":"Guenter","family":"Steiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieve","family":"Van Hoovels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f3ra","family":"Csige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariele","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Iagnocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2023.103421_bb0005","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103421_bb0010","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European league against rheumatism\/American College of Rheumatology Classification Criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103421_bb0015","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (Part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103421_bb0020","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s13075-021-02687-5","article-title":"Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications","volume":"23","author":"Volkov","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103421_bb0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/annrheumdis-2013-203565","article-title":"Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis","volume":"74","author":"Rombouts","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103421_bb0030","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41584-019-0244-4","article-title":"The structure, specificity and function of anti-citrullinated protein antibodies","volume":"15","author":"Ge","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2023.103421_bb0035","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41467-023-36257-x","article-title":"A subset of antibodies targeting citrullinated proteins confers protection from rheumatoid arthritis","volume":"14","author":"He","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2023.103421_bb0040","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/art.30100","article-title":"Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology\/European league against rheumatism criteria","volume":"63","author":"van der Linden","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103421_bb0045","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/rheumatology\/keq442","article-title":"Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria","volume":"50","author":"Kaneko","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103421_bb0050","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1136\/ard.2010.143560","article-title":"Performance of the 2010 ACR\/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort","volume":"70","author":"Cader","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103421_bb0055","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1136\/ard.2010.142299","article-title":"Diagnostic performance of the ACR\/EULAR 2010 criteria for rheumatoid arthritis and two diagnostic algorithms in an early arthritis clinic (REACH)","volume":"70","author":"Alves","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103421_bb0060","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1136\/annrheumdis-2012-201909","article-title":"Application of the 2010 ACR\/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort","volume":"72","author":"Biliavska","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103421_bb0065","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103421_bb0070","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/annrheumdis-2017-212365","article-title":"Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR\/EULAR classification of rheumatoid arthritis","volume":"77","author":"Van Hoovels","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103421_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-211039","article-title":"Anticitrullinated protein antibodies: taking into account antibody levels improves interpretation","volume":"76","author":"Bossuyt","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103421_bb0080","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/ar2903","article-title":"The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis","volume":"12","author":"Pruijn","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103421_bb0085","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.autrev.2012.05.007","article-title":"Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis","volume":"12","author":"Trouw","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103421_bb0090","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/annrheumdis-2016-209991","article-title":"Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands","volume":"76","author":"van Zanten","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103421_bb0095","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1136\/annrheumdis-2017-211325","article-title":"Differences in the symptomatic phase preceding ACPA-positive and ACPA-negative RA: a longitudinal study in arthralgia during progression to clinical arthritis","volume":"76","author":"Burgers","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103421_bb0100","first-page":"69","article-title":"IgM levels and IgM-mediated immune responses in patients with acute hepatitis A, acute hepatitis B and chronic HB antigenaemia","volume":"23","author":"Dietz","year":"1976","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2023.103421_bb0105","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000066861","article-title":"Rheumatoid factors in health and disease: structure, function, induction and regulation","volume":"6","author":"Haberman","year":"2003","journal-title":"Curr Dir Autoimmun"},{"key":"10.1016\/j.autrev.2023.103421_bb0110","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1136\/annrheumdis-2012-202127","article-title":"A prediction rule for the development of arthritis in seropositive arthralgia patients","volume":"72","author":"van de Stadt","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103421_bb0115","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/art.39297","article-title":"Autoantibodies in prediction of the development of rheumatoid arthritis among healthy relatives of patients with the disease","volume":"67","author":"Ramos-Remus","year":"2015","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103421_bb0120","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/annrheumdis-2016-209794","article-title":"Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present","volume":"76","author":"Derksen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103421_bb0125","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.clinthera.2019.04.017","article-title":"Predicting rheumatoid arthritis in at-risk individuals","volume":"41","author":"van Boheemen","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.autrev.2023.103421_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002099","article-title":"A multicenter study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein\/peptide antibodies test results","volume":"8","author":"Van Hoovels","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2023.103421_bb0135","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/ard.2009.122473","article-title":"The stop arthritis very early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis","volume":"69","author":"Machold","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103421_bb0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/annrheumdis-2017-212763","article-title":"Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study","volume":"78","author":"Gerlag","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103421_bb0145","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s13063-019-3403-7","article-title":"Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-Centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol","volume":"20","author":"Al-Laith","year":"2019","journal-title":"Trials."},{"key":"10.1016\/j.autrev.2023.103421_bb0150","series-title":"Rheumatoid Arthritis Nature Reviews Disease Primers","first-page":"18001","volume":"4","author":"Smolen","year":"2018"},{"key":"10.1016\/j.autrev.2023.103421_bb0155","first-page":"83","article-title":"Early arthritis. Rheumatoid arthritis: even earlier \u2026","volume":"58","author":"Szekanecz","year":"2017","journal-title":"Hung Rheumatol"},{"key":"10.1016\/j.autrev.2023.103421_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2022.100142","article-title":"Impact of autoimmune serology test results on RA classification and diagnosis","volume":"5","author":"Van Hoovels","year":"2022","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.autrev.2023.103421_bb0165","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/annrheumdis-2015-208980","article-title":"How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins","volume":"76","author":"Hensvold","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103421_bb0170","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00296-019-04492-5","article-title":"ACPA-positive versus ACPA-negative rheumatoid arthritis: two distinct erosive disease entities on radiography and ultrasonography","volume":"40","author":"Grosse","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2023.103421_bb0175","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/s13075-014-0483-3","article-title":"Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts","volume":"16","author":"Humphreys","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103421_bb0180","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/acr.22296","article-title":"Mortality trends in patients with early rheumatoid arthritis over 20 years: results from the Norfolk arthritis register","volume":"66","author":"Humphreys","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2023.103421_bb0185","first-page":"32","article-title":"Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis","volume":"10","author":"Kapitany","year":"2008","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2023.103421_bb0190","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/art.34421","article-title":"Very high levels of anti-citrullinated protein antibodies are associated with HLA-DRB1*15 non-shared epitope allele in patients with rheumatoid arthritis","volume":"64","author":"Laki","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103421_bb0195","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2016-209297","article-title":"Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs","volume":"76","author":"Figueiredo","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103421_bb0200","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13075-018-1520-4","article-title":"Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes","volume":"20","author":"de Moel","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103421_bb0205","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1136\/annrheumdis-2021-221849","article-title":"Standardisation of ACPA tests: evaluation of a new candidate reference preparation","volume":"81","author":"Van Hoovels","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T19:48:59Z","timestamp":1712519339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223001556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1568997223001556"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103421","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should ACR\/EULAR criteria be revised changing the RF and ACPA scores?","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103421","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103421"}}